Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Amgen Kicks Off Stand-Alone Biz in Japan, Eyes Simultaneous Launch of Full Pipeline
Amgen launched its stand-alone operations in Japan on April 1, marking a departure from its joint venture business with local partner Astellas Pharma as originally planned, with its country chief Steve Sugino vowing that the big biotech aims for global…
To read the full story
Related Article
- Amgen Astellas BioPharma to Become Amgen’s Wholly Owned Subsidiary; Continue Copromotion with Astellas
January 24, 2020
- Amgen to Remain Active Investor in Japan as It Eyes 2020 Launch of Stand-Alone Subsidiary
October 4, 2018
- Astellas, Amgen Clinch Strategic Alliance on 5 Products; JV to Begin Operations in October
May 30, 2013
BUSINESS
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
- Nipro Pharma Recalls Topical Drugs over Long-Running Manufacturing Deviations
July 16, 2026
- JCR to File DMD Drug Givinostat in Japan by End-2026
July 16, 2026
- Daiichi Sankyo Healthcare to Take Over Claritin EX Sales in Japan
July 16, 2026
- Maruishi Set to Secure Japan Rights to Kringle’s Vocal Fold Scar Drug
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…